​

Funding Round

Series C - ADARx Pharmaceuticals

Series C - ADARx Pharmaceuticals

Investment Firm

Overview

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Announced Date

Aug 09, 2023

Closed on Date

Aug 09, 2023

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

TCG Crossover

TCG Crossover

TCG Crossover is a late_stage_venture and private_equity firm.

Bain Capital Life Sciences

Bain Capital Life Sciences

Bain Capital Life Sciences is a early_stage_venture and private_equity and venture firm.

Participant Investors

15

Investor Name
Participant InvestorT. Rowe Price
Participant InvestorLilly Asia Ventures
Participant InvestorInvus
Participant InvestorVivo Capital
Participant InvestorBlackRock

Round Details and Background

ADARx Pharmaceuticals raised $200000000 on 2023-08-09 in Series C

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 12, 2020
Venture Round - ADARx Pharmaceuticals
-6.0M
Sep 08, 2021
Series B - ADARx Pharmaceuticals
4-75.0M
Jan 20, 2023
Series B - ADARx Pharmaceuticals
5-46.0M
Aug 09, 2023
Series C - ADARx Pharmaceuticals
16-200.0M

Recent Activity

There is no recent news or activity for this profile.